GlaxoSmithKline plc (GSKN) — Capital Reinvestment Ratio
Latest as of September 2025:
0.40x
GlaxoSmithKline plc (GSKN) has a Capital Reinvestment Ratio of 0.40x as of September 2025, meaning it reinvests 0% of its operating cash flow (MX$2.22 Billion) in capital expenditures (MX$879.00 Million). See GSKN free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.40x
Capex / Operating Cash Flow
Operating Cash Flow
MX$2.22 Billion
MXN
Capital Expenditures
MX$879.00 Million
MXN
Data as of
Sep 2025
Most recent filing
GlaxoSmithKline plc Capital Reinvestment Ratio (2013–2024)
This chart tracks GlaxoSmithKline plc's Capital Reinvestment Ratio across 12 annual periods.
Annual Capital Reinvestment Ratio for GlaxoSmithKline plc (2013–2024)
Year-by-year Capital Reinvestment Ratio for GlaxoSmithKline plc from 2013 to 2024. For live market cap and broader valuation context, see GlaxoSmithKline plc (GSKN) market capitalisation.
| Year | Reinvestment Ratio | Operating CF (MXN) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.45x | MX$6.55 Billion | MX$2.98 Billion | ▲ +7.8% |
| 2023 | 0.42x | MX$5.48 Billion | MX$2.31 Billion | ▲ +173.4% |
| 2022 | 0.15x | MX$7.40 Billion | MX$1.14 Billion | ▲ +29.2% |
| 2021 | 0.12x | MX$7.95 Billion | MX$950.00 Million | ▲ +2.0% |
| 2020 | 0.12x | MX$8.44 Billion | MX$989.00 Million | ▼ -25.7% |
| 2019 | 0.16x | MX$8.02 Billion | MX$1.26 Billion | ▼ -1.2% |
| 2018 | 0.16x | MX$8.42 Billion | MX$1.34 Billion | ▼ -28.5% |
| 2017 | 0.22x | MX$6.92 Billion | MX$1.54 Billion | ▼ -38.3% |
| 2016 | 0.36x | MX$6.50 Billion | MX$2.35 Billion | ▼ -32.6% |
| 2015 | 0.54x | MX$2.57 Billion | MX$1.38 Billion | ▲ +134.0% |
| 2014 | 0.23x | MX$5.18 Billion | MX$1.19 Billion | ▲ +39.5% |
| 2013 | 0.16x | MX$7.22 Billion | MX$1.19 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow